Chinese Drugmaker's IPO Tests a Slumping Biotech Market

Get the Full StoryA Chinese cancer drug developer is pushing ahead with an initial public offering in Hong Kong, despite a global markets rout and the recent poor performance of other biotechnology startups that have listed in the city.

Share: